Identification of immune-related genes that predict prognosis and risk of bladder cancer: bioinformatics analysis of TCGA database.
The Cancer Genome Atlas
bioinformatics analysis
bladder cancer
immune-related genes
prognosis
Journal
Aging
ISSN: 1945-4589
Titre abrégé: Aging (Albany NY)
Pays: United States
ID NLM: 101508617
Informations de publication
Date de publication:
30 07 2021
30 07 2021
Historique:
received:
19
05
2020
accepted:
06
07
2021
pubmed:
31
7
2021
medline:
12
1
2022
entrez:
30
7
2021
Statut:
ppublish
Résumé
Bladder cancer (BLCA) is the major tumor of the urinary system, and immune-related genes (IRGs) contribute significantly to its initiation and prognosis. A total of 51 prognostic IRGs significantly associated with overall survival were identified. Functional enrichment analysis revealed that these genes were actively involved in tumor-related functions and pathways. Using multivariate Cox regression analysis, we detected 11 optimal IRGs (ADIPOQ, PPY, NAMPT, TAP1, AHNAK, OLR1, PDGFRA, IL34, MMP9, RAC3, and SH3BP2). We validated the prognostic value of this signature in two validation cohorts: GSE13507 (n = 165) and GSE32894 (n = 224). Furthermore, we performed a western blot and found that the expression of these IRGs matched their mRNA expression in TCGA. Moreover, correlations between risk score and immune-cell infiltration indicated that the prognostic signature reflected infiltration by several types of immune cells. We identified and validated an 11-IRG-based risk signature that may be a reliable tool to evaluate the prognosis of BLCA patients and help to devise individualized immunotherapies. Bioinformatics analysis was performed using TCGA and ImmPort databases. Cox regression was used to identify prognostic signatures. Two external GEO cohorts and western blotting of samples were performed to validate the IRG signature.
Sections du résumé
BACKGROUND
Bladder cancer (BLCA) is the major tumor of the urinary system, and immune-related genes (IRGs) contribute significantly to its initiation and prognosis.
RESULTS
A total of 51 prognostic IRGs significantly associated with overall survival were identified. Functional enrichment analysis revealed that these genes were actively involved in tumor-related functions and pathways. Using multivariate Cox regression analysis, we detected 11 optimal IRGs (ADIPOQ, PPY, NAMPT, TAP1, AHNAK, OLR1, PDGFRA, IL34, MMP9, RAC3, and SH3BP2). We validated the prognostic value of this signature in two validation cohorts: GSE13507 (n = 165) and GSE32894 (n = 224). Furthermore, we performed a western blot and found that the expression of these IRGs matched their mRNA expression in TCGA. Moreover, correlations between risk score and immune-cell infiltration indicated that the prognostic signature reflected infiltration by several types of immune cells.
CONCLUSION
We identified and validated an 11-IRG-based risk signature that may be a reliable tool to evaluate the prognosis of BLCA patients and help to devise individualized immunotherapies.
METHODS
Bioinformatics analysis was performed using TCGA and ImmPort databases. Cox regression was used to identify prognostic signatures. Two external GEO cohorts and western blotting of samples were performed to validate the IRG signature.
Identifiants
pubmed: 34329197
pii: 203333
doi: 10.18632/aging.203333
pmc: PMC8386543
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
19352-19374Références
Cancer Cell. 2010 Apr 13;17(4):348-61
pubmed: 20385360
J Mol Biol. 1992 Nov 20;228(2):433-41
pubmed: 1453454
Mol Cell Proteomics. 2018 Sep;17(9):1788-1802
pubmed: 29950347
Lancet Oncol. 2017 Nov;18(11):1483-1492
pubmed: 28967485
Horm Cancer. 2010 Jun;1(3):136-45
pubmed: 21761356
Biosci Rep. 2018 Sep 5;38(5):
pubmed: 30054424
Lancet. 2017 Jan 7;389(10064):67-76
pubmed: 27939400
J Cardiovasc Magn Reson. 2012 Nov 30;14:83
pubmed: 23199362
Oncol Lett. 2018 Feb;15(2):1616-1620
pubmed: 29434857
Int J Cancer. 2012 Mar 1;130(5):1109-19
pubmed: 21480223
Bioinformatics. 2011 Feb 1;27(3):431-2
pubmed: 21149340
Bioinformatics. 2009 Apr 15;25(8):1091-3
pubmed: 19237447
Cancer Manag Res. 2020 Mar 13;12:1941-1946
pubmed: 32214851
Eur Urol. 2017 Mar;71(3):447-461
pubmed: 27324428
Lancet. 2016 May 7;387(10031):1909-20
pubmed: 26952546
Minerva Urol Nefrol. 2020 Apr;72(2):207-213
pubmed: 31144487
Clin Lab. 2017 Mar 1;63(3):479-485
pubmed: 28271680
APMIS. 2020 Feb;128(2):92-103
pubmed: 31755155
Lancet Oncol. 2017 Mar;18(3):312-322
pubmed: 28131785
Urol Oncol. 2013 Feb;31(2):241-6
pubmed: 21292512
Cancer Res. 2017 Nov 1;77(21):e19-e22
pubmed: 29092931
Front Genet. 2019 Nov 22;10:1187
pubmed: 31824575
Aging (Albany NY). 2019 Sep 3;11(17):6930-6940
pubmed: 31479417
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Oncol Lett. 2018 Oct;16(4):5186-5190
pubmed: 30250586
Int J Clin Exp Pathol. 2020 Dec 01;13(12):2937-2949
pubmed: 33425095
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Bioinformatics. 2013 Mar 1;29(5):661-3
pubmed: 23325622
Nat Rev Urol. 2019 Oct;16(10):613-630
pubmed: 31501534
Front Oncol. 2020 Jan 09;9:1484
pubmed: 31993369
Int J Clin Exp Pathol. 2013 May 15;6(6):1150-6
pubmed: 23696935
Asian Pac J Cancer Prev. 2015;16(8):3425-8
pubmed: 25921156
JAMA Oncol. 2018 Apr 1;4(4):537-544
pubmed: 29423515
J Am Coll Cardiol. 2004 Apr 7;43(7):1195-200
pubmed: 15063429
Pathol Int. 2009 Apr;59(4):247-50
pubmed: 19351368
Croat Med J. 2014 Oct;55(5):507-13
pubmed: 25358883
J Immunother Cancer. 2017 Nov 21;5(1):94
pubmed: 29157296
Cell. 2017 Oct 19;171(3):540-556.e25
pubmed: 28988769
Front Mol Biosci. 2020 Aug 31;7:218
pubmed: 33062641
Sci Data. 2018 Feb 27;5:180015
pubmed: 29485622
Immunol Res. 2014 May;58(2-3):234-9
pubmed: 24791905
Clin Transl Med. 2020 Dec;10(8):e263
pubmed: 33377649
Front Genet. 2020 Feb 05;11:12
pubmed: 32117435
Eur Urol. 2018 Feb;73(2):149-152
pubmed: 28917596
J Clin Oncol. 2000 Sep;18(17):3068-77
pubmed: 11001674
Cancer Gene Ther. 2021 Jan 5;:
pubmed: 33402733
Curr Cancer Drug Targets. 2013 Jan;13(1):57-68
pubmed: 22920439
Eur Urol. 2017 Mar;71(3):462-475
pubmed: 27375033
Diagnostics (Basel). 2019 Dec 28;10(1):
pubmed: 31905599